お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:特発性肺線維症(IPF):2029年までの機会分析と予測
市場調査レポート
商品コード
970308

特発性肺線維症(IPF):2029年までの機会分析と予測

Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)

出版日: | 発行: GlobalData | ページ情報: 英文 121 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
特発性肺線維症(IPF):2029年までの機会分析と予測
出版日: 2021年04月15日
発行: GlobalData
ページ情報: 英文 121 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

特発性肺線維症(IPF)市場の成長要因には、臨床におけるアンメットニーズを満たすことを目指している製薬企業による、収益性の高い治療薬の承認が挙げられ、現在の治療法の普及と新製品の承認の増加が予測期間中の同市場成長の主な推進力となる見通しです。

当レポートは、主要7ヶ国(米国、EU5ヵ国、日本)の特発性肺線維症(IPF)市場について調査しており、疾患の概要、疫学、COVID-19の影響、アンメットニーズ、機会と戦略、パイプライン評価分析などの情報を提供しています。

目次

第1章 目次

  • 表のリスト
  • 図のリスト

第2章 エグゼクティブサマリー

  • IPF市場の予測期間における控えめな成長
  • 革新的な小規模製薬企業の開発を維持するための提携の必要性
  • 高いアンメットニーズ
  • 多くの異なる作用機序の中で革新された後期パイプライン
  • 医師の見解

第3章 イントロダクション

  • 触媒
  • 関連レポート
  • 今後の関連レポート

第4章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 分類またはステージングシステム
    • GAPモデル
    • 努力性肺活量(FVC)の低下による階層化

第5章 疫学

  • 病気の背景
  • 危険因子と併存疾患
  • 世界の動向
  • 予測調査手法
  • IPFの疫学予測(2019-2029)
    • IPFの診断された症例
    • IPFの性別診断症例
    • IPFの年齢別診断症例
    • IPFの診断された有病率
    • 性別:診断されたIPFの有病率
    • 年齢別:診断されたIPFの有病率
    • 重症度別:IPFの一般的な症例の診断
    • 併存疾患別:IPFの一般的な症例の診断
    • IPFの有病率の合計
  • 討論
    • 疫学的予測の洞察
    • COVID-19の影響
    • 分析の限界
    • 分析の強み

第6章 現在の治療オプション

  • 概要
  • 現在の治療ガイドライン
  • 症候性治療

第7章 アンメットニーズと機会の評価

  • 概要
  • 早期診断
  • 医薬品の安全性と有効性の向上
  • 患者の生活の質の改善
  • 重度の病気の患者のための治療

第8章 R&D戦略

  • 概要
    • 企業提携
    • 併用療法
  • 臨床試験デザイン
    • 適切なエンドポイント
    • 生活の質の測定の使用の増加
    • 標準治療へのアドオン
    • 患者集団の選択

第9章 IPF疾患空間に対するCOVID-19の影響

  • 概要
  • ケアの継続性
  • トライアルロジスティクス
  • 病気の空間への長期的な影響

第10章 パイプライン評価

  • 概要
  • 革新的な初期段階のアプローチ

第11章 パイプライン評価分析

  • 主要なパイプライン薬の臨床ベンチマーク
  • 主要なパイプライン薬の商業的ベンチマーク
  • 競争力のある評価
  • 主要ラインの10年間の予測
    • 米国
    • EU5ヵ国
    • 日本

第12章 付録

図表

List of Tables

List of Tables

  • Table 1: IPF: Key Metrics in the 7MM
  • Table 2: The GAP Index
  • Table 3: Risk Factors and Comorbidities for IPF
  • Table 4: Diagnosed Prevalent Cases of IPF by Comorbidities, N, Both Sexes, Ages ≥18 Years, 2019
  • Table 5: Treatment Guidelines for IPF, 2020
  • Table 6: Leading Treatments for IPF, 2020
  • Table 7: Early Stage Pipeline Agents for IPF, 2020
  • Table 8: Clinical Benchmark of Key Pipeline Drugs - IPF
  • Table 9: Commercial Benchmark of Key Pipeline Drugs - IPF
  • Table 10: IPF Market - Global Drivers and Barriers, 2019-2029
  • Table 11: Key Events Impacting US Sales for IPF, 2019-2029
  • Table 12: Key Events Impacting 5EU Sales for IPF, 2019-2029
  • Table 13: Key Events Impacting Japan Sales for IPF, 2019-2029
  • Table 14: Key Historical and Projected Launch Dates for IPF
  • Table 15: Key Historical and Projected Patent Expiry Dates for IPF
  • Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for IPF in 2019 and 2029
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC), Esbriet and Ofev
  • Figure 3: The Induction and Progression of IPF
  • Figure 4: 7MM, Diagnosed Incidence of IPF (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019
  • Figure 5: 7MM, Diagnosed Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
  • Figure 6: 7MM, Total Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
  • Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of IPF
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Severity
  • Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Comorbidities
  • Figure 10: 7MM, Diagnosed Incident Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 11: 7MM, Diagnosed Incident Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
  • Figure 12: 7MM, Diagnosed Incident Cases of IPF by Age, N, Both Sexes, 2019
  • Figure 13: 7MM, Diagnosed Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 14: 7MM, Diagnosed Prevalent Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
  • Figure 15: 7MM, Diagnosed Prevalent Cases of IPF by Age, N, Both Sexes, 2019
  • Figure 16: 7MM, Diagnosed Prevalent Cases of IPF by Severity, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 17: 7MM, Total Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 18: Unmet Needs and Opportunities in IPF
  • Figure 19: Overview of the Development Pipeline in IPF
  • Figure 20: Key Phase II/III Trials for Therapeutic Agents that Target IPF Disease Progression
  • Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC)
  • Figure 22: Global (7MM) Sales Forecast by Country for IPF in 2019 and 2029
  • Figure 23: Global Sales Forecast by Molecule for IPF in 2019 and 2029
  • Figure 24: Sales Forecast by Class for IPF in the US in 2019 and 2029
  • Figure 25: Sales Forecast by Class for IPF in the 5EU in 2019 and 2029
  • Figure 26: Sales Forecast by Class for IPF in Japan in 2019 and 2029
目次
Product Code: GDHC122POA

Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule treatments; Roche's Esbriet and Boehringer Ingelheim's Ofev. The landscape will continue to evolve and the increasing uptake of current therapies and approval of new products will be the primary drivers of growth over the forecast period.

The catalyst for this event-driven update is the discontinuation of GLPG-1690 by Gilead/Galapagos for development in all indications, including IPF and Systemic Sclerosis (SSc) in Q1 2021. Due to IPF's high clinical unmet needs, the discontinuation of GLPG-1690 represents a major setback in the disease space, since ziritaxestat was expected to be the first late-state pipeline product to launch for IPF in the next several years. The next earliest pipeline agent set to launch is pamrevlumab in 2024.

Key Highlights

  • The greatest drivers of growth in the global IPF market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the IPF market include low diagnostic and treatment rates and the patent expiries of both Ofev and Esbriet in all markets.
  • The late-stage pipeline products are completely distinct mechanisms of action both from each other and the available marketed therapies.
  • The most important unmet needs in the IPF market are improved drug safety and efficacy and improvement in patient quality of life.

KEY QUESTIONS ANSWERED

  • Which unmet needs are limiting the treatment of IPF in the 7MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for IPF? How should these strategies differ across different geographical markets?
  • What effect will the launch of generics have on the sales of branded agents?
  • What are the main R&D trends in the IPF market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
  • What was the impact of the COVID-19 pandemic on the IPF treatment, clinical trial conduct, and looking forward?

Scope

  • Overview of IPF including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline IPF market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting IPF therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global IPF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global IPF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global IPF therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Idiopathic Pulmonary Fibrosis: Executive Summary

  • 2.1 IPF Market to Experience Conservative Growth over the Forecast Period
  • 2.2 Innovative Small Pharma Require Partnerships to Sustain Development
  • 2.3 High Unmet Clinical Needs Remain
  • 2.4 Late-Stage Pipeline Fractured Among Many Differing Mechanisms of Action
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems
    • 4.2.1 GAP Model
    • 4.2.2 Stratification by Decline in Forced Vital Capacity (FVC)

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for IPF (2019-2029)
    • 5.5.1 Diagnosed Incident Cases of IPF
    • 5.5.2 Sex-Specific Diagnosed Incident Cases of IPF
    • 5.5.3 Age-Specific Diagnosed Incident Cases of IPF
    • 5.5.4 Diagnosed Prevalent Cases of IPF
    • 5.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF
    • 5.5.6 Age-Specific Diagnosed Prevalent Cases of IPF
    • 5.5.7 Diagnosed Prevalent Cases of IPF by Severity
    • 5.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities
    • 5.5.9 Total Prevalent Cases of IPF
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Coronavirus Disease 2019 (COVID-19) Impact
    • 5.6.3 Limitations of Analysis
    • 5.6.4 Strengths of Analysis

6 Current Treatment Options

  • 6.1 Overview
  • 6.2 Current Treatment Guidelines
  • 6.3 Symptomatic Treatments

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Earlier Diagnosis
  • 7.3 Improved Drug Safety and Efficacy
  • 7.4 Improvement in Patient Quality of Life
  • 7.5 Treatments for Patients with Severe Disease

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Corporate Partnerships
    • 8.1.2 Combination Therapy
  • 8.2 Clinical Trial Design
    • 8.2.1 Appropriate Endpoints
    • 8.2.2 Increased Use of Quality of Life Measures
    • 8.2.3 Add-Ons to Standard of Care
    • 8.2.4 Selection of Patient Population

9 Impact of COVID-19 on the IPF Disease Space

  • 9.1 Overview
  • 9.2 Continuity of Care
  • 9.3 Trial Logistics
    • 9.3.1 Recruitment
    • 9.3.2 Trial Conduct in Isolation
    • 9.3.3 Supply Chain
  • 9.4 Long-Term Impact on the Disease Space

10 Pipeline Assessment

  • 10.1 Overview
  • 10.2 Innovative Early-Stage Approaches

11 Pipeline Valuation Analysis

  • 11.1 Clinical Benchmark of Key Pipeline Drugs
  • 11.2 Commercial Benchmark of Key Pipeline Drugs
  • 11.3 Competitive Assessment
  • 11.4 Top-Line 10-Year Forecast
    • 11.4.1 US
    • 11.4.2 5EU
    • 11.4.3 Japan

12 Appendix

  • 12.1 Bibliography
  • 12.2 Abbreviations
  • 12.3 Methodology
    • 12.3.1 Forecasting Methodology
    • 12.3.2 Diagnosed Patients
    • 12.3.3 Percent Drug-Treated Patients
    • 12.3.4 Drugs Included in Each Therapeutic Class
    • 12.3.5 Launch and Patent Expiry Dates
    • 12.3.6 General Pricing Assumptions
    • 12.3.7 Individual Drug Assumptions
    • 12.3.8 Generic Erosion
    • 12.3.9 Pricing of Pipeline Agents
  • 12.4 Primary Research - KOLs Interviewed for This Report
    • 12.4.1 KOLs
    • 12.4.2 Payers
  • 12.5 Primary Research - Prescriber Survey
  • 12.6 About the Authors
    • 12.6.1 Analyst
    • 12.6.2 Therapy Area Director
    • 12.6.3 Epidemiologist
    • 12.6.4 Managing Epidemiologist
    • 12.6.5 Global Director of Therapy Analysis and Epidemiology
    • 12.6.6 Global Head and EVP of Healthcare Operations and Strategy
  • 12.7 About GlobalData
  • 12.8 Contact Us
  • 12.9 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.